OnCo
technologiesTechnologyEstablished

Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)

Where the radioactive atoms for imaging and therapy actually come from: ageing reactors, new accelerators, and a scramble for actinium.

Mo-99/Tc-99m for SPECT still depends on a few research reactors (BR2, HFR Petten, OPAL, SAFARI) with accelerator alternatives from NorthStar and SHINE. Lu-177 (non-carrier-added) is supplied by ITM, SHINE, Eckert & Ziegler, Curium and NorthStar; Ac-225 supply is the binding constraint for alpha therapy, with US DOE, TerraPower Isotopes, Orano Med (Pb-212), NorthStar, Niowave, and ITM expanding. Supply agreements are now a competitive asset for radiopharma companies.

Generic schematic · not to scale · placeholder for the radiopharma front
Receptor (PSMA / SSTR) · Ligand + Lu-177 · β⁻ track ~2 mm, crossfire

How it works

Reactor neutron capture (Lu-176→Lu-177), Th-229 decay chains and accelerator spallation (Ac-225), and electron-accelerator photonuclear routes (Mo-99) produce isotopes that are purified, calibrated, and shipped against decay.

Strengths
  • Multiple new non-reactor routes since 2020
Limitations
  • Ac-225 shortage until late 2020s
  • Reactor outages cause global shortages
  • Regulatory licensing of new production sites is slow

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Therapeutic isotope supply chain" OR ABSTRACT:"Therapeutic isotope supply chain" OR TITLE:"Mo-99, Lu-177, Ac-225" OR ABSTRACT:"Mo-99, Lu-177, Ac-225") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), not a curated reading list.

Connected

11top